Shockwave Medical, Inc. (SWAV)

$199.1

-6.34

(-3.09%)▲

Market is closed - opens 7 PM, 02 Oct 2023

Performance

  • $198.00
    $206.46
    $199.10
    downward going graph

    0.55%

    Downside

    Day's Volatility :4.1%

    Upside

    3.56%

    downward going graph
  • $172.50
    $320.54
    $199.10
    downward going graph

    13.36%

    Downside

    52 Weeks Volatility :46.18%

    Upside

    37.89%

    downward going graph

Returns

PeriodShockwave Medical, Inc.
3 Months
-30.24%
6 Months
-7.03%
1 Year
-28.4%
3 Years
165.57%

Highlights

Market Capitalization
8.2B
Book Value
$16.8
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
6.47
PE Ratio
34.38
Wall Street Target Price
284.89
Profit Margin
39.56%
Operating Margin TTM
24.55%
Return On Assets TTM
15.72%
Return On Equity TTM
52.91%
Revenue TTM
616.6M
Revenue Per Share TTM
16.98
Quarterly Revenue Growth YOY
49.2%
Gross Profit TTM
424.7M
EBITDA
158.4M
Diluted Eps TTM
6.47
Quarterly Earnings Growth YOY
0.12
EPS Estimate Current Year
3.56
EPS Estimate Next Year
4.4
EPS Estimate Current Quarter
0.85
EPS Estimate Next Quarter
0.93

Analyst Recommendation

Buy
    73%Buy
    20%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Shockwave Medical, Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
3
3
3
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 43.09%

Current $199.10
Target $284.89

Company Financials

FY17Y/Y Change
Revenue
1.7M
-
Net Income
-30.6M
-
Net Profit Margin
-1.8K%
-
FY18Y/Y Change
Revenue
12.3M
↑ 613.38%
Net Income
-41.1M
↑ 34.25%
Net Profit Margin
-335.17%
↑ 1445.81%
FY19Y/Y Change
Revenue
42.9M
↑ 250.05%
Net Income
-51.1M
↑ 24.35%
Net Profit Margin
-119.06%
↑ 216.11%
FY20Y/Y Change
Revenue
67.8M
↑ 57.92%
Net Income
-65.7M
↑ 28.55%
Net Profit Margin
-96.92%
↑ 22.14%
FY21Y/Y Change
Revenue
237.1M
↑ 249.83%
Net Income
-9.1M
↓ 86.09%
Net Profit Margin
-3.85%
↑ 93.07%
FY22Y/Y Change
Revenue
489.7M
↑ 106.51%
Net Income
216.0M
↓ 2464.23%
Net Profit Margin
44.1%
↑ 47.95%
Q1 FY22Q/Q Change
Revenue
93.6M
↑ 11.22%
Net Income
14.5M
↑ 12.2%
Net Profit Margin
15.51%
↑ 0.14%
Q2 FY22Q/Q Change
Revenue
120.7M
↑ 28.96%
Net Income
25.6M
↑ 76.03%
Net Profit Margin
21.17%
↑ 5.66%
Q3 FY22Q/Q Change
Revenue
131.3M
↑ 8.77%
Net Income
35.0M
↑ 36.94%
Net Profit Margin
26.65%
↑ 5.48%
Q4 FY22Q/Q Change
Revenue
144.0M
↑ 9.67%
Net Income
140.9M
↑ 302.57%
Net Profit Margin
97.84%
↑ 71.19%
Q1 FY23Q/Q Change
Revenue
161.1M
↑ 11.83%
Net Income
39.1M
↓ 72.23%
Net Profit Margin
24.29%
↓ 73.55%
Q2 FY23Q/Q Change
Revenue
180.2M
↑ 11.86%
Net Income
28.9M
↓ 26.23%
Net Profit Margin
16.02%
↓ 8.27%
FY17Y/Y Change
Total Assets
59.3M
-
Total Liabilities
142.6M
-
FY18Y/Y Change
Total Assets
53.4M
↓ 9.92%
Total Liabilities
22.9M
↓ 83.95%
FY19Y/Y Change
Total Assets
231.9M
↑ 334.17%
Total Liabilities
39.3M
↑ 71.63%
FY20Y/Y Change
Total Assets
262.7M
↑ 13.25%
Total Liabilities
46.4M
↑ 18.08%
FY21Y/Y Change
Total Assets
345.7M
↑ 31.61%
Total Liabilities
103.9M
↑ 123.88%
FY22Y/Y Change
Total Assets
646.1M
↑ 86.9%
Total Liabilities
134.8M
↑ 29.77%
Q1 FY22Q/Q Change
Total Assets
372.5M
↑ 7.76%
Total Liabilities
104.7M
↑ 0.81%
Q2 FY22Q/Q Change
Total Assets
417.1M
↑ 11.98%
Total Liabilities
112.1M
↑ 7.05%
Q3 FY22Q/Q Change
Total Assets
475.8M
↑ 14.06%
Total Liabilities
119.9M
↑ 6.96%
Q4 FY22Q/Q Change
Total Assets
646.1M
↑ 35.79%
Total Liabilities
134.8M
↑ 12.42%
Q1 FY23Q/Q Change
Total Assets
783.2M
↑ 21.23%
Total Liabilities
212.6M
↑ 57.72%
Q2 FY23Q/Q Change
Total Assets
786.6M
↑ 0.43%
Total Liabilities
169.7M
↓ 20.17%
FY17Y/Y Change
Operating Cash Flow
-30.3M
-
Investing Cash Flow
-2.2M
-
Financing Cash Flow
33.7M
-
FY18Y/Y Change
Operating Cash Flow
-41.5M
↑ 36.64%
Investing Cash Flow
-174.0K
↓ 92.2%
Financing Cash Flow
29.8M
↓ 11.51%
FY19Y/Y Change
Operating Cash Flow
-48.1M
↑ 16.02%
Investing Cash Flow
-59.5M
↑ 34120.11%
Financing Cash Flow
208.1M
↑ 597.95%
FY20Y/Y Change
Operating Cash Flow
-71.2M
↑ 47.97%
Investing Cash Flow
-107.5M
↑ 80.5%
Financing Cash Flow
90.0M
↓ 56.72%
FY21Y/Y Change
Operating Cash Flow
15.0M
↓ 121.12%
Investing Cash Flow
26.4M
↓ 124.58%
Financing Cash Flow
-2.5M
↓ 102.72%
Q1 FY22Q/Q Change
Operating Cash Flow
1.9M
↓ 90.7%
Investing Cash Flow
-27.4M
↑ 18.67%
Financing Cash Flow
2.5M
↑ 404.0%
Q2 FY22Q/Q Change
Operating Cash Flow
28.9M
↑ 1390.5%
Investing Cash Flow
5.8M
↓ 121.22%
Financing Cash Flow
500.0K
↓ 80.16%
Q3 FY22Q/Q Change
Operating Cash Flow
34.5M
↑ 19.46%
Investing Cash Flow
-5.3M
↓ 190.72%
Financing Cash Flow
383.0K
↓ 23.4%
Q1 FY23Q/Q Change
Operating Cash Flow
34.0M
↓ 35.23%
Investing Cash Flow
6.2M
-
Financing Cash Flow
83.4M
↑ 769.21%
Q2 FY23Q/Q Change
Operating Cash Flow
39.7M
↑ 17.0%
Investing Cash Flow
-83.8M
↓ 1455.03%
Financing Cash Flow
-95.8M
↓ 214.9%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Shockwave Medical, Inc.
Shockwave Medical, Inc.
-10.48%
-7.03%
-28.4%
165.57%
552.79%
Stryker Corporation
Stryker Corporation
-3.93%
-4.97%
30.23%
30.96%
52.96%
Boston Scientific Corp.
Boston Scientific Corp.
-1.53%
6.19%
32.4%
38.18%
35.45%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-9.3%
-15.69%
-16.16%
-13.2%
21.67%
Abbott Laboratories
Abbott Laboratories
-5.83%
-4.67%
-2.68%
-10.85%
30.67%
Medtronic Plc
Medtronic Plc
-4.59%
-1.64%
-2.96%
-24.6%
-21.24%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Shockwave Medical, Inc.
Shockwave Medical, Inc.
34.38
34.38
NA
3.56
0.53
0.16
0.0
16.8
Stryker Corporation
Stryker Corporation
38.6
38.6
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
90.46
90.46
2.53
2.0
0.05
0.04
0.0
12.46
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
31.09
31.09
3.07
2.55
0.22
0.12
0.0
10.49
Abbott Laboratories
Abbott Laboratories
33.49
33.49
18.76
4.39
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
29.04
29.04
3.04
5.28
0.07
0.04
0.04
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Shockwave Medical, Inc.
Shockwave Medical, Inc.
Buy
$8.2B
552.79%
34.38
39.56%
Stryker Corporation
Stryker Corporation
Buy
$103.8B
52.96%
38.6
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$78.1B
35.45%
90.46
6.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.5B
21.67%
31.09
24.56%
Abbott Laboratories
Abbott Laboratories
Buy
$170.3B
30.67%
33.49
12.83%
Medtronic Plc
Medtronic Plc
Buy
$104.7B
-21.24%
29.04
11.47%

Institutional Holdings

  • BlackRock Inc

    9.90%

  • Vanguard Group Inc

    9.80%

  • FMR Inc

    6.63%

  • Wellington Management Company LLP

    3.68%

  • Artisan Partners Limited Partnership

    3.12%

  • T. Rowe Price Associates, Inc.

    2.97%

Company Information

shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen

Organization
Shockwave Medical, Inc.
Employees
1001
CEO
Mr. Douglas E. Godshall M.B.A.
Industry
Medical Specialties

Discover More

FAQs